CCL4 and nonpapillary renal cell carcinoma: In view of the above results, it is reasonable to conclude that CCL4 may serve as an indicator for clinical use of immune checkpoint inhibitors (ICIs) and be conducive to predict ICI efficacy in ccRCC patients subjected to immunotherapy.